Page last updated: 2024-08-23

cabergoline and pasireotide

cabergoline has been researched along with pasireotide in 23 studies

Research

Studies (23)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (8.70)	29.6817
2010's	17 (73.91)	24.3611
2020's	4 (17.39)	2.80

Authors

Authors	Studies
Barlier, A; Culler, MD; Dufour, H; Fusco, A; Germanetti, AL; Gunz, G; Jaquet, P; Saveanu, A	1
Alexandraki, KI; Grossman, AB	1
Ambrosio, MR; Buratto, M; Degli Uberti, EC; Filieri, C; Lapparelli, M; Minoia, M; Scanarini, M; Tagliati, F; Zatelli, MC	1
de Bruin, C; de Herder, WW; de Jong, FH; Feelders, RA; Hermus, AR; Hofland, LJ; Lamberts, SW; Netea-Maier, RT; Pereira, AM; Romijn, JA; van der Lely, AJ; van Heerebeek, R; Zelissen, PM	1
de Bruin, C; de Herder, WW; de Jong, FH; de Maat, MP; Feelders, RA; Hermus, AR; Hofland, LJ; Lamberts, SW; Leebeek, FW; Netea-Maier, RT; Pereira, AM; Rijken, DC; Romijn, JA; van der Lely, AJ; van der Pas, R; Zelissen, PM	1
Barahona Constanzo, MJ; del Pozo Picó, C	1
de Bruin, C; de Herder, WW; de Jong, FH; Feelders, RA; Hermus, AR; Hofland, LJ; Lamberts, SW; Netea-Maier, RT; Pereira, AM; Romijn, JA; van der Lely, AJ; van der Pas, R; Webb, SM; Zelissen, PM	1
Nieman, LK	1
Góth, M	1
Gadelha, MR; Vieira Neto, L	1
Danser, AH; de Bruin, C; Feelders, RA; Hofland, LJ; Lamberts, SW; Netea-Maier, R; Pereira, AM; Sprij-Mooij, DM; van den Berg-Garrelds, IM; van den Meiracker, AH; van der Pas, R; van Esch, JH; van Schaik, RH; Zelissen, PM	1
Hamrahian, AH; Hoffman, AR; Yuen, KC	1
Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS	1
Ciresi, A; Giordano, C; Guarnotta, V; Radellini, S	1
Feelders, RA; Hofland, LJ; Lacroix, A; Newell-Price, J; Nieman, LK; Pivonello, R	1
Reincke, M; Theodoropoulou, M	1
Bolanowski, M; Hubalewska-Dydejczyk, A; Kos-Kudła, B; Lewiński, A; Ruchała, M; Zgliczyński, W	1
Biller, BMK; Tritos, NA	1
Colwell, HH; Fleseriu, M; Fogelfeld, L; Gordon, MB; Haviv, A; Ludlam, WH; Mathias, SD; Sisco, J	1
Duskin-Bitan, H; Shimon, I	1
Kawakami, K; Matsubayashi, K	1
Gadelha, MR; Shimon, I; Wildemberg, LE	1
Bex, M; Biller, BMK; Boguszewski, CL; Chattopadhyay, A; Feelders, RA; Fleseriu, M; González-Devia, D; Kadioglu, P; Maamari, R; Patino, H; Pedroncelli, AM; Pivonello, R; Yavuz, DG	1

Reviews

11 review(s) available for cabergoline and pasireotide

Article	Year
Pituitary-targeted medical therapy of Cushing's disease. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:5 Topics: Adrenocorticotropic Hormone; Animals; Cabergoline; Dopamine Agonists; Ergolines; Humans; Neurotransmitter Agents; Oligopeptides; Pituitary ACTH Hypersecretion; Pituitary Gland; Somatostatin	2008
New prospects for drug treatment in Cushing disease. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2012, Volume: 59, Issue:10 Topics: Adenoma; Adrenocorticotropic Hormone; Animals; Cabergoline; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Ergolines; Etomidate; Humans; Hydrocortisone; Imidazoles; Ketoconazole; Metyrapone; Mice; Mifepristone; Mitotane; Multicenter Studies as Topic; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; PPAR gamma; Pyridines; Rats; Somatostatin; Therapies, Investigational; Tretinoin	2012
Update in the medical therapy of Cushing's disease. Current opinion in endocrinology, diabetes, and obesity, 2013, Volume: 20, Issue:4 Topics: Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Humans; Hydrocortisone; Pituitary ACTH Hypersecretion; Somatostatin	2013
[Drug therapy for acromegaly]. Orvosi hetilap, 2013, Sep-29, Volume: 154, Issue:39 Topics: Acromegaly; Aminoquinolines; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Interdisciplinary Communication; Membrane Proteins; Octreotide; Patient Care Team; Peptides, Cyclic; Pituitary Neoplasms; Somatostatin	2013
Efficacy of medical treatment in Cushing's disease: a systematic review. Clinical endocrinology, 2014, Volume: 80, Issue:1 Topics: Cabergoline; Ergolines; Female; Humans; Ketoconazole; Male; Metyrapone; Mitotane; Pituitary ACTH Hypersecretion; Somatostatin	2014
AACE/ACE Disease State Clinical Review: Medical Management of Cushing Disease. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2014, Volume: 20, Issue:7 Topics: Adrenocorticotropic Hormone; Cabergoline; Drug Therapy, Combination; Ergolines; Humans; Ketoconazole; Mifepristone; Pituitary ACTH Hypersecretion; Somatostatin	2014
Advances in the medical treatment of Cushing's syndrome. The lancet. Diabetes & endocrinology, 2019, Volume: 7, Issue:4 Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cabergoline; Cushing Syndrome; Dopamine Agonists; ErbB Receptors; Gefitinib; Hormones; Humans; Imidazoles; Isoquinolines; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Pyrazoles; Pyridines; Receptors, Glucocorticoid; Roscovitine; Somatostatin; Temozolomide; Tretinoin	2019
Tumor-Directed Therapeutic Targets in Cushing Disease. The Journal of clinical endocrinology and metabolism, 2019, 03-01, Volume: 104, Issue:3 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents; Cabergoline; Clinical Trials as Topic; Corticotrophs; Humans; Pituitary ACTH Hypersecretion; Roscovitine; Silybin; Somatostatin; Treatment Outcome; Tretinoin	2019
Medical Management of Cushing Disease. Neurosurgery clinics of North America, 2019, Volume: 30, Issue:4 Topics: Cabergoline; Etomidate; Humans; Ketoconazole; Metyrapone; Mitotane; Pituitary ACTH Hypersecretion; Somatostatin; Temozolomide; Treatment Outcome	2019
Prolactinomas in males: any differences? Pituitary, 2020, Volume: 23, Issue:1 Topics: Cabergoline; Dopamine Agonists; Humans; Hypogonadism; Male; Pituitary Neoplasms; Prolactinoma; Somatostatin; Temozolomide	2020
Pituitary acting drugs: cabergoline and pasireotide. Pituitary, 2022, Volume: 25, Issue:5 Topics: Cabergoline; Humans; Pituitary ACTH Hypersecretion; Pituitary Gland; Somatostatin	2022

Trials

3 trial(s) available for cabergoline and pasireotide

Article	Year
Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. The New England journal of medicine, 2010, May-13, Volume: 362, Issue:19 Topics: Adult; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Pituitary ACTH Hypersecretion; Prospective Studies; Receptors, Dopamine D2; Receptors, Somatostatin; Somatostatin	2010
The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:4 Topics: Adult; Aged; Blood Coagulation; Blood Coagulation Factors; Cabergoline; Dopamine Agonists; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Ergolines; Fibrinolysis; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Hormones, Anterior; Remission Induction; Somatostatin; Thrombophilia; Young Adult	2012
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease. Frontiers in endocrinology, 2023, Volume: 14 Topics: Cabergoline; Cushing Syndrome; Humans; Hydrocortisone; Pituitary ACTH Hypersecretion; Treatment Outcome	2023

Other Studies

9 other study(ies) available for cabergoline and pasireotide

Article	Year
Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. European journal of endocrinology, 2008, Volume: 158, Issue:5 Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Ergolines; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Ligands; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2; Receptors, Somatostatin; RNA, Messenger; Somatostatin; Tumor Cells, Cultured	2008
Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:2 Topics: Adenoma; Aged; Apoptosis; Cabergoline; Cell Line, Tumor; Cell Survival; Ergolines; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Pituitary Neoplasms; Receptors, Somatostatin; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Somatostatin; Vascular Endothelial Growth Factor A	2010
Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease. Pituitary, 2013, Volume: 16, Issue:4 Topics: Adult; Aged; Cabergoline; Circadian Rhythm; Dopamine Agonists; Ergolines; Female; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Pituitary ACTH Hypersecretion; Quality of Life; Somatostatin; Surveys and Questionnaires; Young Adult	2013
Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy. European journal of endocrinology, 2014, Volume: 170, Issue:2 Topics: Adult; Aged; Aldosterone; Angiotensinogen; Animals; Cabergoline; Ergolines; Female; Humans; Hypertension; Iliac Artery; In Vitro Techniques; Male; Middle Aged; Pituitary ACTH Hypersecretion; Rats; Renin; Renin-Angiotensin System; Somatostatin; Vasoconstriction	2014
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:8 Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Cabergoline; Comorbidity; Enzyme Inhibitors; Ergolines; Female; Follow-Up Studies; Hirsutism; Hormone Antagonists; Hormones; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ketoconazole; Male; Metyrapone; Middle Aged; Mifepristone; Muscle Weakness; Muscular Atrophy; Neurosurgical Procedures; Obesity, Abdominal; Pituitary ACTH Hypersecretion; Pituitary Irradiation; Polycystic Ovary Syndrome; Retrospective Studies; Rosiglitazone; Somatostatin; Striae Distensae; Thiazolidinediones; Treatment Outcome; Tumor Burden; Young Adult	2017
Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report. BMC endocrine disorders, 2018, Jan-24, Volume: 18, Issue:1 Topics: Acromegaly; Adult; Antineoplastic Agents; Cabergoline; Drug Therapy, Combination; Ergolines; Hormones; Human Growth Hormone; Humans; Male; Prognosis; Salvage Therapy; Somatostatin	2018
Diagnostics and treatment of acromegaly - updated recommendations of the Polish Society of Endocrinology. Endokrynologia Polska, 2019, Volume: 70, Issue:1 Topics: Acromegaly; Cabergoline; Endocrinology; Female; Human Growth Hormone; Humans; Male; Pituitary Neoplasms; Poland; Societies, Medical; Somatostatin	2019
Development of a novel patient-reported measure for acromegaly: the Acro-TSQ. Pituitary, 2019, Volume: 22, Issue:6 Topics: Acromegaly; Adult; Bromocriptine; Cabergoline; Female; Human Growth Hormone; Humans; Interviews as Topic; Male; Middle Aged; Octreotide; Peptides, Cyclic; Personal Satisfaction; Somatostatin; Surveys and Questionnaires	2019
Prevalence, incidence, comorbidities, and treatment patterns among Japanese patients with acromegaly: a descriptive study using a nationwide claims database. Endocrine journal, 2020, Oct-28, Volume: 67, Issue:10 Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Comorbidity; Dopamine Agonists; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hyperlipidemias; Hypertension; Incidence; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Prevalence; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Somatostatin; Young Adult	2020